{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T09:26:01Z","timestamp":1748251561986,"version":"3.40.5"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Stage III non\u2010small\u2010cell lung cancer (NSCLC) management is challenging given the heterogeneous nature of the disease. The LATAM subset of the real\u2010world, global KINDLE study reported the treatment patterns and clinical outcomes for LATAM from the pre\u2010immuno\u2010oncology era.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study was conducted in seven countries (Argentina, Chile, Colombia, Dominican Republic, Mexico, Peru and Uruguay) in stage III NSCLC (American Joint Committee on Cancer, 7th edition) diagnosed between January 2013 and December 2017. Retrospective data from patients' medical records (index date to the end of follow\u2010up) were collected. Summary statistics, Kaplan\u2013Meier survival estimates and a two\u2010sided 95% confidence interval (CI) were provided. Cox proportional hazard model was used for univariate and multi\u2010variate analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 231 patients was enrolled, the median age was 65.0\u2009years (range 21.0\u201389.0), 60.6% were males, 76.6% had smoking history, 64.0% had adenocarcinoma and 28.7% underwent curative resection. Multiple treatment regimens (&gt;25) were used; chemotherapy alone was the most common (24.8%). The overall median progression\u2010free survival (mPFS) and median overall survival (mOS) were 14.8\u00a0months (95% CI, 12.1\u201318.6) and 48.6\u00a0months (95% CI, 34.7 to not calculable). Significantly better mPFS and mOS were observed for stage IIIA with curative surgery and resectable tumours and stage IIIB with an Eastern Cooperative Oncology Group score of 0\/1, female gender, resectable tumours, adenocarcinoma and curative surgery (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Results show diversity in treatment practices and the corresponding clinical outcomes in stage III NSCLC. There is a need to streamline treatment selection and sequencing to decrease relapse rates after initial therapy.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4990","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T06:18:19Z","timestamp":1657001899000},"page":"1247-1259","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real\u2010world <scp>KINDLE\u2010Latin<\/scp> America subset data on treatment patterns and clinical outcomes in patients with stage <scp>III<\/scp> non\u2010small\u2010cell lung cancer"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4135-7332","authenticated-orcid":false,"given":"Claudio Marcelo","family":"Martin","sequence":"first","affiliation":[{"name":"Instituto Alexander Fleming  Buenos Aires Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Puello\u2010Guerrero","sequence":"additional","affiliation":[{"name":"Universidad Aut\u00f3noma de Santo Domingo (UASD), Instituto Nacional del C\u00e1ncer (INCART)  Santo Domingo Dominican Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Alberto","family":"Mas\u2010Lopez","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Enfermedades Neopl\u00e1sicas and Oncosalud\u2010AUNA  Lima Peru"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saul","family":"Campos\u2010G\u00f3mez","sequence":"additional","affiliation":[{"name":"Centro Oncol\u00f3gico Estatal Instituto de Seguridad Social del Estado de M\u00e9xico y Municipios  Toluca Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"Orlando\u2010Orlandi","sequence":"additional","affiliation":[{"name":"Instituto Nacional del T\u00f3rax  Santiago Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Fernando","family":"Tejado Gallegos","sequence":"additional","affiliation":[{"name":"AstraZeneca  Mexico City Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reto","family":"Huggenberger","sequence":"additional","affiliation":[{"name":"AstraZeneca  Baar Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.02.014"},{"key":"e_1_2_13_3_1","unstructured":"The Global Cancer Observatory.Factsheets Latin America and the Caribbean. Updated December2020.https:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/904\u2010latin\u2010america\u2010and\u2010the\u2010caribbean\u2010fact\u2010sheets.pdf. Accessed 20 February 2020."},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2016.05.003"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2016.06.07"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-0985-4"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.21037\/qims.2018.08.02"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0024-2019"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.026"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx222"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.013052"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.4401"},{"key":"e_1_2_13_13_1","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non\u2010small Cell Lung Cancer V.5.2021. \u00a9 National Comprehensive Cancer Network Inc.2021.All rights reserved. Accessed [June 17 2021]. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02098-5"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.8_suppl.231"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.018"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S125070"},{"key":"e_1_2_13_18_1","first-page":"2234","article-title":"New advances in immunotherapy for non\u2010small cell lung cancer","volume":"10","author":"Qin H","year":"2018","journal-title":"Am J Transl Res"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00131"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.08.1281"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.05.003"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181577511"},{"volume-title":"IMFINZI (durvalumab) injection, for intravenous use","year":"2020","key":"e_1_2_13_24_1"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.062"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0041-87812004000300005"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezu411"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.3023"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0449-8"},{"key":"e_1_2_13_30_1","first-page":"141","article-title":"Lung cancer in Brazil: epidemiology and treatment challenges","volume":"7","author":"S\u00e1 VK","year":"2016","journal-title":"Lung Cancer (Auckl)"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-018-0556-7"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31822f655f"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.e18114"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4990","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4990","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T13:47:22Z","timestamp":1692452842000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1002\/cam4.4990"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4990","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"type":"print","value":"2045-7634"},{"type":"electronic","value":"2045-7634"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"assertion":[{"value":"2022-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}